Farideh Bagherzadeh-Khiabani

Dr. Farideh Bagherzadeh-Khiabani

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2024 in Cancers
Verified
Journal Article
Open access
PDF file
KHKristen E. Howell
Kristen E. Howell
JBJessica L Baedke
Jessica L Baedke
FBFarideh Bagherzadeh-Khiabani
Farideh Bagherzadeh-Khiabani
AMAaron McDonald
Aaron McDonald
Paul NathanPaul Nathan
Paul Nathan
IHI-Chan Huang
I-Chan Huang
Background: Cancer therapies predispose survivors to a high symptom burden. This study utilized mobile health (mHealth) technology to assess the feasibility of collecting daily symptoms from adult survivors of childhood cancer to evaluate symptom fluctuation and associations with future health-related quality-of-life (HRQOL). Methods: This prospective study used an mHealth platform to distribute a 20-item cancer-related symptom survey (5 consecutive days each month) and an HRQOL survey (the day after the symptom survey) over 3 consecutive months to participants from the Childhood Cancer Survivor Study. These surveys comprised a PROMIS-29 Profile and Neuro-QOL assessed HRQOL. Daily symptom burden was calculated by summing the severity (mild, moderate, or severe) of 20 symptoms. Univariate linear mixed-effects models were used to analyze total, person-to-person, day-to-day, and month-to-month variability for the burden of 20 individual symptoms. Multivariable linear regression was used to analyze the association between daily symptom burden in the first month and HRQOL in the third month, adjusted for covariates. Results: Out of the 60 survivors invited, 41 participated in this study (68% enrollment rate); 83% reported their symptoms ≥3 times and 95% reported HRQOL in each study week across 3 months. Variability of daily symptom burden differed from person-to-person (74%), day-to-day (18%), and month-to-month (8%). Higher first-month symptom burden was associated with poorer HRQOL related to anxiety (regression coefficient: 6.56; 95% CI: 4.10–9.02), depression (6.32; 95% CI: 3.18–9.47), fatigue (7.93; 95% CI: 5.11–10.80), sleep (6.07; 95% CI: 3.43–8.70), pain (5.16; 95% CI: 2.11–8.22), and cognitive function (–6.89; 95% CI: –10.00 to –3.79) in the third month. Conclusions: Daily assessment revealed fluctuations in symptomology, and higher symptom burden was associated with poorer HRQOL in the future. Utilizing mHealth technology for daily symptom assessment improves our understanding of symptom dynamics and sources of variability.

10 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
FBFarideh Bagherzadeh-Khiabani
Farideh Bagherzadeh-Khiabani
Kevin KrullKevin Krull
Kevin Krull
SIShizue Izumi
Shizue Izumi
SMSedigheh Mirzaei
Sedigheh Mirzaei
TZTiange Zheng
Tiange Zheng
IHI-Chan Huang
I-Chan Huang
Background: Adult survivors of childhood cancer face a significant risk for treatment-related late effects that may impair health-related quality of life (HRQoL). Incorporating longitudinal changes in patient-reported symptoms beyond treatment-based risk factors may enhance the prediction of HRQoL. Methods: Survivors (n = 576) dually enrolled in the St. Jude Lifetime Cohort Study and Childhood Cancer Survivor Study reported 37 symptoms across 10 domains at three time points over 20 years to ascertain longitudinal symptom change patterns. HRQoL was subsequently assessed using SF-36 scores. Prediction models were developed using Bayesian Information Criterion Elastic Net (BIEN), first including demographic, diagnosis, and treatment variables, then adding symptom change patterns. Prediction of suboptimal HRQoL (score < 40) was evaluated using 10-fold cross-validated area under the receiver operating characteristic curve values (AUC). Results: Participants (median baseline age 26.7 years, 52% female, 90% non-Hispanic white, 41% leukemia, and 30% Hodgkin/non-Hodgkin lymphoma survivors) most frequently reported symptom domains of sensory, pain, and anxiety (50–60% at any time point), followed by depression and memory (40–50%). Consistent absence throughout follow-up was the most common pattern (41.7–98.1%), while patterns requiring symptom presence at ≥1 time point were less common (0.0–16.7%), and persistent presence throughout follow-up was rare (0.0–6.8%). Across 10 SF36-HRQoL scores, symptom-enhanced models improved prediction over non-symptom models (AUCs 0.75–0.85 vs. 0.56–0.66; p-values < 0.001). Conclusions: Longitudinal symptom change patterns substantially improved future HRQoL prediction, achieving prediction accuracy that may be of clinical effectiveness. This supports regular symptom assessment and further research towards symptom-informed risk stratification in survivorship care.

30 July 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
KHKristen E. Howell
Kristen E. Howell
JBJessica L Baedke
Jessica L Baedke
FBFarideh Bagherzadeh-Khiabani
Farideh Bagherzadeh-Khiabani
AMAaron McDonald
Aaron McDonald
Paul NathanPaul Nathan
Paul Nathan
IHI-Chan Huang
I-Chan Huang
Background: Cancer therapies predispose survivors to a high symptom burden. This study utilized mobile health (mHealth) technology to assess the feasibility of collecting daily symptoms from adult survivors of childhood cancer and evaluate symptom fluctuation and associations with future health-related quality-of-life (HRQOL). Methods: A prospective study using an mHealth platform to distribute a 20-item cancer-related symptom survey (5 consecutive days each month) and an HRQOL survey (the day after symptom survey) over 3 consecutive months to participants from the Childhood Cancer Survivor Study. PROMIS-29 Profile and Neuro-QOL assessed HRQOL. Daily symptom burden was calculated by summing the severity (mild, moderate, or severe) of 20 symptoms. Univariate linear mixed-effects models analyzed total, person-to-person, day-to-day, and month-to-month variability for the burden of 20 individual symptoms. Multivariable linear regression analyzed the association between daily symptom burden in the first month and HRQOL in the third month, adjusting covariates. Results: Out of the 60 survivors invited, 41 participated in this study (68% enrollment rate); 83% reported their symptoms ≥3 times and 95% reported HRQOL, both in each week across 3 months. Variability of daily symptom burden differed from person-to-person (74%), day-to-day (18%), and month-to-month (8%). Higher first-month symptom burden was associated with poorer HRQOL related to anxiety (regression coefficient: 6.56; 95%CI: 4.10-9.02), depression (6.32; 95%CI: 3.18-9.47), fatigue (7.93; 95%CI: 5.11-10.80), sleep (6.07; 95%CI: 3.43-8.70), pain (5.16; 95%CI: 2.11-8.22), and cognitive function (-6.89; 95%CI: -10.00 to -3.79) in the third month. Conclusion: Daily assessment reveals fluctuations in symptomology, and higher symptom burden was associated with poorer HRQOL in the future. Utilizing mHealth technology for daily symptom assessment improves our understanding of symptom dynamics and sources of variability.